0001178913-25-001497 Sample Contracts

TERMINATION AGREEMENT
Termination Agreement • April 29th, 2025 • Sol-Gel Technologies Ltd. • Pharmaceutical preparations • New York

This Termination Agreement (this “Agreement”) is effective as of April 17, 2025 (the “Effective Date”) and is entered into by and between Galderma Holding SA, with an office at Avenue D’Ouchy 4, 1006 Lausanne, Switzerland (“Galderma”), and Sol-Gel Technologies Ltd., with a principal place of business at 7 Golda Meir St., Ness Ziona 7403620, Israel (“Sol-Gel”). Each of Galderma and Sol-Gel is sometimes referred to individually herein as a “Party” and collectively as the “Parties.” Capitalized terms used but not defined herein shall have the meaning set forth in the License Agreements (as defined below).

View Source
CERTAIN IDENTIFIED INFORMATION MARKED [***] HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. TERMINATION AGREEMENT
Termination Agreement • April 29th, 2025 • Sol-Gel Technologies Ltd. • Pharmaceutical preparations • New York

This Termination Agreement ("Agreement") is entered into as of August 15, 2024 ("Effective Date"), between Padagis Israel Pharmaceuticals Ltd, a limited liability company organized in Israel ("Padagis"), and Sol-Gel Technologies Ltd., a limited liability company organized in Israel ("Sol-Gel"). Padagis and Sol-Gel are individually referred to as a "Party" and collectively referred to as the "Parties."

View Source
PRODUCT PURCHASE AGREEMENT BY AND BETWEEN MAYNE PHARMA LLC AND SOL-GEL TECHNOLOGIES LTD.
Product Purchase Agreement • April 29th, 2025 • Sol-Gel Technologies Ltd. • Pharmaceutical preparations • New York

THIS PRODUCT PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of [■], 202[■] (“Effective Date”) between Sol-Gel Technologies Ltd., with a principal place of business at 7 Golda Meir St., Ness Ziona 7403620, Israel (“Sol-Gel”), and Mayne Pharma LLC a company organized under the laws of Delaware having its principal place of business at 3301 Benson Dr., Suite 401, Raleigh, NC 27609. (“Mayne”). Sol-Gel and Mayne may be referred to herein individually as a “Party” and collectively as the “Parties.”

View Source
CERTAIN IDENTIFIED INFORMATION MARKED [***] HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.
Asset Purchase Agreement • April 29th, 2025 • Sol-Gel Technologies Ltd. • Pharmaceutical preparations • New York

This ASSET PURCHASE AGREEMENT (this “Agreement”) is made as of May 15, 2024, by and among Sol-Gel Technologies Ltd., a company organized under the laws of Israel, with its principle executive offices at 7 Golda Meir Street Ness Ziona 7403650, Israel (“Seller”) and Shenzhen Beimei Pharmaceutical Co., Ltd., a company organized and existing under the laws of the PRC, with registered office at Room 1501, 1502, 1503 and 1505 of Unit 1, Building A, Kexing Science Park, No. 15 Keyuan Road, Kejiyuan Community, Yuehai Sub-District, Nanshan District, Shenzhen 518057, Guangdong, the PRC (together with its designated Affiliates, “Purchaser”). Seller and Purchaser are each referred to individually as a “Party” and together as the “Parties”.

View Source